Choosing between scale-out and scale-up is one of the most consequential decisions in biologics manufacturing. The choice determines your facility layout, capital requirements, regulatory filing strategy, and how resilient your supply chain is to batch failures. As single-use bioreactor technology has matured and cell culture titers have climbed above 5 g/L for monoclonal antibodies, scale-out has shifted from a niche clinical-supply approach to a viable commercial manufacturing strategy. This guide compares both approaches across cost, risk, regulatory burden, and facility design, with a worked example showing how the economics play out for a 100 kg/year mAb program.
What Scale-Out and Scale-Up Mean
Scale-up is the traditional approach: increase bioreactor volume at each manufacturing stage, progressing from bench-scale (2-10 L) through pilot (50-500 L) to production (2,000-15,000 L or larger). Each volume increase requires re-optimization of mixing, aeration, and heat transfer to maintain equivalent mass transfer and shear conditions.
Scale-out keeps the bioreactor at the same volume used during clinical manufacturing and adds more units running in parallel. Instead of one 10,000 L stainless-steel vessel, a scale-out facility might run five 2,000 L single-use bioreactors simultaneously. The total working volume is equivalent, but each individual bioreactor operates under identical conditions to the clinical-scale process.
The distinction matters because biological processes are sensitive to physical environment changes. Mixing time in a 15,000 L bioreactor can exceed 60 seconds compared to 15-30 seconds at 2,000 L. Dissolved CO2 accumulation, hydrostatic pressure gradients, and tip speed all shift with vessel geometry. Scale-out avoids these translation challenges entirely.
Side-by-Side Comparison
Scale-out and scale-up differ across nearly every operational dimension. The table below summarizes the key trade-offs that drive the decision between the two strategies for a typical monoclonal antibody or recombinant protein program.
| Dimension | Scale-Up | Scale-Out |
|---|---|---|
| Typical vessel size | 2,000-15,000 L (stainless steel) | 200-4,000 L (single-use) |
| CAPEX | $150-400M for greenfield facility | $50-150M for equivalent output |
| Facility build time | 36-48 months | 18-24 months |
| Process transfer risk | High (new mixing, aeration, heat transfer) | Low (same vessel as clinical scale) |
| Batch failure impact | 100% of lot lost | Only affected unit lost (e.g., 17% for 1-of-6) |
| Capacity flexibility | Fixed (vessel size determines output) | Modular (add/remove units as demand shifts) |
| Consumable cost per batch | Low (reusable vessels) | Higher ($50-150 per bag per unit) |
| CIP/SIP requirement | Yes (dedicated systems, validation) | No (disposable contact surfaces) |
| Labor per batch | Lower (single unit to monitor) | Higher (multiple parallel units) |
| Changeover time | Days to weeks (CIP/SIP/validation) | Hours (bag change) |
| Multi-product capability | Requires dedicated suites or extensive cleaning | Rapid changeover enables multi-product in same suite |
| Best suited for | High-volume products (>500 kg/year) | Low-to-medium volume (<200 kg/year) |
The comparison shows that neither strategy dominates across all dimensions. Scale-up excels at unit economics for high-volume products where stainless-steel infrastructure can be amortized across thousands of batches. Scale-out excels at speed-to-market, risk mitigation, and flexibility for portfolios with uncertain demand.
Cost Analysis: CAPEX, OPEX, and COGS
The total cost of manufacturing is the combination of upfront facility investment (CAPEX) and ongoing operational costs (OPEX) amortized across annual output. Scale-out and scale-up have fundamentally different cost profiles that favor different production volumes.
CAPEX differences. A greenfield stainless-steel mAb facility with 2 x 15,000 L bioreactors costs $250-400M and takes 3-4 years to build. An equivalent-output scale-out facility using 6 x 2,000 L single-use bioreactors costs $80-150M and can be operational in 18-24 months. The savings come from eliminating CIP/SIP infrastructure, reducing cleanroom classification requirements (the bioreactor contact path is pre-sterilized), and using ballroom layouts instead of dedicated suites.
OPEX differences. Scale-out incurs higher per-batch costs: single-use bags ($50-150 each), more QC release testing (one lot per bioreactor or pooled with additional testing), and more operators managing parallel units. Scale-up has higher fixed costs (utility infrastructure, CIP/SIP chemicals, water systems) but lower marginal costs per batch.
The crossover point where scale-up becomes cheaper depends on titer, batch success rate, and facility utilization. For a 5 g/L mAb process, the crossover is typically around 150-200 kg/year output. Below this, the CAPEX advantage of scale-out dominates. Above it, the lower per-batch OPEX of stainless steel pulls ahead.
| Annual Output (kg) | Scale-Up COGS ($/g) | Scale-Out COGS ($/g) | Favored Strategy |
|---|---|---|---|
| 25 | $380-500 | $180-280 | Scale-out |
| 50 | $220-320 | $150-230 | Scale-out |
| 100 | $140-200 | $120-180 | Scale-out (marginal) |
| 200 | $90-130 | $100-150 | Crossover zone |
| 500 | $50-80 | $80-120 | Scale-up |
| 1,000 | $30-55 | $65-100 | Scale-up |
Fermentation Economics Calculator
Model COGS per gram for your specific process. Compare batch, fed-batch, and continuous modes with custom media, labor, and facility costs.
Batch Failure Risk and Supply Security
Batch failure risk is where scale-out delivers its most compelling advantage. In a single-vessel scale-up process, any contamination, equipment failure, or out-of-spec event means the entire production lot is lost. In a scale-out configuration, only the affected bioreactor is lost while the remaining units continue to produce.
Industry-wide batch success rates for mammalian cell culture are approximately 95%, meaning roughly 1 in 20 batches fails. For a company producing a gene therapy or orphan drug from a single 2,000 L bioreactor, each failure directly delays patient supply. With six parallel 2,000 L bioreactors, a single failure reduces output by 17% rather than 100%.
The risk advantage extends beyond contamination. Scale-out also protects against:
- Supply chain disruption. If a specific bag lot has a defect, only the units using that lot are affected.
- Equipment downtime. Maintenance on one bioreactor does not halt the entire facility.
- Demand variability. Units can be added or removed as market demand shifts, without the sunk cost of an oversized vessel.
- Regulatory holds. If one bioreactor lot is under investigation, product from the other units can still be released.
WuXi Biologics has reported a 99% batch success rate across more than 300 large-scale single-use batches, compared to the industry average of roughly 95% for stainless-steel operations. This higher success rate in single-use systems likely reflects the elimination of CIP/SIP validation failures and cross-contamination risks from shared equipment.
Process Transfer and Regulatory Considerations
Scale-out significantly simplifies process transfer from clinical to commercial manufacturing. Because the bioreactor volume does not change, the process operates under identical physical conditions (mixing time, kLa, P/V, tip speed) at both stages. This eliminates the comparability studies and bridging data that regulators require when vessel geometry changes.
In a scale-up approach, the BLA or MAA filing must include data demonstrating that the commercial-scale process produces equivalent product quality to the clinical-scale process. This typically requires 3-5 comparability batches at the new scale, adding 6-12 months and $5-15M to the development timeline.
Scale-out validation uses a bracket design: validate the process at the single-unit level, then demonstrate equivalence when multiple units are pooled. Because all units are identical, the number of PPQ batches can be reduced compared to a scale-up campaign where each vessel volume is a separate scale.
More than 10 commercial programs using scale-out strategies have successfully completed process performance qualification campaigns and been submitted to FDA, EMA, or NMPA. Regulatory agencies have accepted scale-out as a valid manufacturing strategy provided that lot definition, pooling criteria, and per-unit release testing are clearly described in the filing.
| Requirement | Scale-Up | Scale-Out |
|---|---|---|
| Comparability studies | Required (clinical vs commercial scale) | Minimal (same scale, bracket validation) |
| PPQ batches | 3-5 at each new scale | 3 at single-unit scale + pooling validation |
| Process characterization | Repeat at commercial scale | Leverage clinical-scale data directly |
| Lot definition | One bioreactor = one lot | Pooled or per-unit (must be pre-defined in filing) |
| Timeline to BLA filing | +6-12 months for scale-up data | Minimal additional time |
| Post-approval scale changes | Prior approval supplement (PAS) | Add units within validated range (CBE-30) |
Scale-Up Calculator
Compare five scale-up criteria side-by-side: constant P/V, tip speed, Reynolds number, kLa, and mixing time. See which parameters change when vessel size increases.
Facility Design Implications
Facility layout differs significantly between the two approaches. Scale-up facilities are typically designed as dedicated manufacturing suites with fixed piping, CIP/SIP systems, and vessel-specific platforms. Scale-out facilities use open ballroom layouts where multiple portable bioreactors can be positioned flexibly.
A scale-out facility using 6 x 2,000 L single-use bioreactors requires roughly 50-60% of the cleanroom footprint of an equivalent stainless-steel facility. The savings come from eliminating CIP/SIP skids, reducing piping runs, and consolidating utility services. Ballroom designs reduce facility footprint by 30-50% compared to traditional suite-based layouts.
Key facility design considerations for each strategy:
- HVAC. Scale-out ballrooms need uniform air handling across the entire room. Scale-up suites can have independent HVAC per suite.
- Utilities. Scale-out requires more distributed utility drops (gas, water, power) across the ballroom floor. Scale-up concentrates utilities at fixed vessel locations.
- Waste handling. Scale-out generates significant solid waste from single-use bags and tubing (estimated 1-2 tonnes per batch per unit). Scale-up generates liquid waste from CIP/SIP cycles.
- Downstream integration. Scale-out may require larger hold vessels or multiple downstream trains if harvests from parallel bioreactors are staggered rather than pooled.
Decision Framework: Which Strategy Fits Your Product?
The choice between scale-out and scale-up depends on your product type, annual volume requirement, portfolio diversity, and risk tolerance. The decision matrix below provides a structured framework for evaluating which strategy best fits your program.
| Factor | Favors Scale-Out | Favors Scale-Up |
|---|---|---|
| Annual demand | <200 kg/year | >500 kg/year |
| Product type | Gene therapy, cell therapy, orphan drug | Blockbuster mAb, biosimilar |
| Demand uncertainty | High (new market, uncertain uptake) | Low (established market, contracted volumes) |
| Portfolio diversity | Multi-product (rapid changeover needed) | Single-product dedicated facility |
| Speed to market | Critical (competitive window) | Not primary driver |
| Risk tolerance | Low (every batch matters for patient supply) | Higher (inventory buffer available) |
| Capital availability | Limited ($50-150M) | Large ($250-400M+) |
| Process titer | >3 g/L (less volume needed per kg product) | <1 g/L (need large vessels to meet demand) |
| Environmental priority | Lower carbon intensity per batch (no CIP steam) | Lower plastic waste per batch |
Hybrid strategies are increasingly the pragmatic choice. A facility might scale up to the largest available single-use bioreactor (currently 4,000-6,000 L) and then scale out by running 4-6 units in parallel. This approach captures the process consistency benefits of single-use technology while achieving effective working volumes of 16,000-24,000 L without any of the scale-up engineering challenges of traditional stainless-steel vessels.
Seed Train Planner
Plan your inoculum expansion from vial thaw to production bioreactor. Calculate split ratios, passage timing, and total media requirements for any vessel train.
Worked Example: 100 kg/year mAb Production
Consider a company manufacturing a monoclonal antibody at 100 kg/year, with a process titer of 5 g/L and 70% downstream recovery. This mid-range volume is squarely in the crossover zone where both strategies are viable.
Worked Example: 100 kg/year mAb, 5 g/L Titer
Step 1: Calculate required upstream output
Upstream output needed = 100 kg / 0.70 DSP recovery = 142.9 kg
Volume needed = 142,900 g / 5 g/L = 28,571 L of harvest
Step 2: Scale-up approach (1 x 15,000 L stainless steel)
Working volume per batch = 15,000 L x 0.80 = 12,000 L
Product per batch = 12,000 L x 5 g/L x 0.70 = 42.0 kg
Batches needed = 100 / 42.0 = 2.4, round up to 3 batches/year
CAPEX = $300M (facility, 36-month build)
Annual OPEX = 3 batches x $250K/batch = $750K
Amortized CAPEX (15 yr) = $20M/year
Total annual cost = $20.75M
COGS/g = $20,750,000 / 100,000 g = $207.50/g
Step 3: Scale-out approach (6 x 2,000 L single-use)
Working volume per batch per unit = 2,000 L x 0.80 = 1,600 L
Product per batch (6 units) = 6 x 1,600 L x 5 g/L x 0.70 = 33.6 kg
Batches needed = 100 / 33.6 = 3.0, round up to 3 campaigns/year
Total batches = 3 campaigns x 6 units = 18 individual batches
CAPEX = $100M (facility, 20-month build)
Annual OPEX = 18 batches x $45K/batch = $810K
Consumables = 18 batches x $8K/batch = $144K
Amortized CAPEX (15 yr) = $6.67M/year
Total annual cost = $7.62M
COGS/g = $7,624,000 / 100,000 g = $76.24/g
Conclusion: At 100 kg/year and 5 g/L titer, scale-out produces a COGS of $76/g compared to $208/g for scale-up. The CAPEX difference ($100M vs $300M) dominates. Scale-up becomes competitive only when the facility is utilized near capacity (producing 400+ kg/year from the same 15,000 L vessel), which brings COGS down to roughly $55-70/g.
Frequently Asked Questions
What is the difference between scale-out and scale-up in biomanufacturing?
Scale-up increases bioreactor volume to meet production demand, typically progressing from 50 L to 500 L to 2,000 L or larger single vessels. Scale-out keeps the bioreactor volume constant and adds more units running in parallel. For example, instead of a single 2,000 L stainless-steel bioreactor, a scale-out facility might operate ten 200 L single-use bioreactors simultaneously. Scale-out preserves the process developed at clinical scale, while scale-up requires re-optimization of mixing, aeration, and heat transfer parameters at each new volume.
Is scale-out cheaper than scale-up for biologics production?
Scale-out typically has lower CAPEX (40-60% less upfront) because it uses smaller single-use bioreactors that do not require dedicated CIP/SIP infrastructure. However, scale-out has higher per-batch OPEX due to consumable bag costs, increased labor for parallel batch management, and more QC testing. The crossover point depends on annual output: below roughly 200 kg/year of mAb, scale-out is often cheaper overall; above 500 kg/year, scale-up in stainless steel becomes more cost-efficient.
How does scale-out reduce batch failure risk?
In a scale-out configuration, losing one bioreactor to contamination or equipment failure means losing only a fraction of the total batch. For example, with six parallel 2,000 L bioreactors, a single failure loses 17% of output rather than 100%. The remaining five bioreactors can still be harvested and pooled. This distributed risk model is especially valuable for gene therapy and cell therapy products where each batch represents significant patient supply.
What products are best suited for scale-out manufacturing?
Scale-out is best suited for low-to-medium volume products including gene therapies (AAV, lentiviral vectors), cell therapies, orphan biologics, biosimilars entering competitive markets, and personalized medicines. These products typically need less than 200 kg/year and benefit from flexible manufacturing where capacity can be adjusted by adding or removing bioreactor units. High-volume blockbuster mAbs producing over 1,000 kg/year generally favor scale-up for lower per-gram costs.
Can you combine scale-out and scale-up in one facility?
Yes, hybrid strategies are increasingly common. A facility might scale up to 2,000 L single-use bioreactors for the upstream process, then scale out by running multiple 2,000 L units in parallel to meet commercial demand. WuXi Biologics operates facilities with four to six 4,000 L single-use bioreactors in parallel, achieving effective working volumes of 16,000-24,000 L. This hybrid approach captures the process consistency benefits of single-use with the throughput advantages of parallel operation.
Related Tools
- Scale-Up Calculator — Compare P/V, tip speed, Re, kLa, and mixing time across bioreactor volumes to see what changes when you scale up.
- Seed Train Planner — Plan your inoculum expansion from vial thaw through production bioreactor, with split ratios and media volumes at each passage.
- Fermentation Economics Calculator — Model COGS per gram across manufacturing modes and compare upstream/downstream cost contributions.
References
- Rouf SA, Moo-Young M, Scharer JM, Douglas PL. Single versus multiple bioreactor scale-up: economy for high-value products. Biochem Eng J. 2000;6(1):25-31. doi:10.1016/S1369-703X(00)00066-8
- Langer ES, Rader RA. Single-use technologies in biopharmaceutical manufacturing: A 10-year review of trends and the future. Eng Life Sci. 2014;14(3):238-243. doi:10.1002/elsc.201300090
- Jacquemart R, Vandersluis M, Zhao M, Sukhija K, Sidhu N, Stout J. A single-use strategy to enable manufacturing of affordable biologics. Comput Struct Biotechnol J. 2016;14:309-318. doi:10.1016/j.csbj.2016.06.007
- Pollock J, Coffman J, Ho SV, Farid SS. Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. Biotechnol Prog. 2017;33(4):854-866. doi:10.1002/btpr.2492
- Lee B, Jung S, Hashimura Y, et al. Cell culture process scale-up challenges for commercial-scale manufacturing of allogeneic pluripotent stem cell products. Bioengineering. 2022;9(3):92. doi:10.3390/bioengineering9030092